Free Trial
NASDAQ:MGX

Metagenomi (MGX) Stock Price, News & Analysis

Metagenomi logo
$1.74 -0.13 (-6.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.81 +0.07 (+4.02%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Metagenomi Stock (NASDAQ:MGX)

Key Stats

Today's Range
$1.73
$1.88
50-Day Range
$1.42
$2.52
52-Week Range
$1.23
$4.92
Volume
281,043 shs
Average Volume
303,231 shs
Market Capitalization
$65.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Metagenomi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

MGX MarketRank™: 

Metagenomi scored higher than 45% of companies evaluated by MarketBeat, and ranked 637th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Metagenomi has only been the subject of 3 research reports in the past 90 days.

  • Read more about Metagenomi's stock forecast and price target.
  • Earnings Growth

    Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

  • Price to Book Value per Share Ratio

    Metagenomi has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Metagenomi's valuation and earnings.
  • Percentage of Shares Shorted

    6.38% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 4.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Metagenomi does not currently pay a dividend.

  • Dividend Growth

    Metagenomi does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.38% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 4.51%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Metagenomi has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Metagenomi this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,800.00 in company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Metagenomi's insider trading history.
Receive MGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MGX Stock News Headlines

FY2025 EPS Estimates for Metagenomi Cut by Chardan Capital
Metagenomi (NASDAQ:MGX) Receives Buy Rating from HC Wainwright
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Metagenomi, Inc. (MGX) Gets a Buy from TD Cowen
See More Headlines

MGX Stock Analysis - Frequently Asked Questions

Metagenomi's stock was trading at $3.61 at the beginning of the year. Since then, MGX shares have decreased by 51.8% and is now trading at $1.74.

Metagenomi, Inc. (NASDAQ:MGX) released its earnings results on Tuesday, August, 12th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.14. The firm earned $8.51 million during the quarter, compared to analysts' expectations of $7.72 million. Metagenomi had a negative net margin of 257.99% and a negative trailing twelve-month return on equity of 37.84%.

Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Top institutional shareholders of Metagenomi include Pura Vida Investments LLC (2.55%), Peapod Lane Capital LLC (1.36%), Geode Capital Management LLC (0.79%) and Norges Bank (0.67%). Insiders that own company stock include Brian C Thomas, Holdings A/S Novo, Sarah B Noonberg and Pamela Wapnick.
View institutional ownership trends
.

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/12/2025
Today
8/29/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGX
Previous Symbol
NASDAQ:MGX
CIK
1785279
Fax
N/A
Employees
236
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$7.00
Potential Upside/Downside
+474.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.06 million
Net Margins
-257.99%
Pretax Margin
-267.38%
Return on Equity
-37.84%
Return on Assets
-27.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.36
Quick Ratio
6.36

Sales & Book Value

Annual Sales
$52.29 million
Price / Sales
1.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.22 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
37,530,000
Free Float
30,852,000
Market Cap
$65.30 million
Optionable
N/A
Beta
-0.12

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:MGX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners